Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
647 clinical trials found
Clinical trials

IBIS

An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS study (ACTRN12621001037897)

Currently recruiting

IDE196-002

IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (NCT05987332)

No longer recruiting

IDE196-009

(NEO)ADJUVANT IDE196 (DAROVASERTIB) IN PATIENTS WITH LOCALIZED OCULAR MELANOMA (NCT05907954)

No longer recruiting

IIHRepurposing1

A phase 2 randomised, placebo- controlled, double-blind pilot trial of drug repurposing in idiopathic intracranial hypertension (ACTRN12625000401459)

Currently recruiting

IKS014-01 IKSUDA

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants with Advanced HER2+ Solid Tumors (NCT05872295)

Currently recruiting

IMC-F106C-101

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers (NCT04262466)

Currently recruiting

IMPAHCT

IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in patients with Pulmonary Arterial Hypertension (PAH). (NCT05036135)

No longer recruiting

INCA 33989-101

A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (NCT05936359)

Currently recruiting

INCA035784-101

A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms (NCT07008118)

This is a Phase 1, multicenter, dose-escalation, and dose-expansion study to investigate the safety, tolerability, PK, PD, and preliminary clinical efficacy of INCA035784 in participants with MPN who are positive for CALR exon-9 mutation. This study will involve Q2W dosing with INCA035784. This IP is a T-cell redirecting bispecific antibody that selectively binds to the N-domain of the surface exposed mCALR and CD3 on T cells, designed to redirect CD3 T cells to recognize and eliminate mCALR-expressing malignant cells.
Currently recruiting

INCB 054707-306 STOP-PN2

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis [STOP-PN2] (NCT06516965)

This study is designed to evaluate the effect of povorcitinib on itch and skin lesions in participants with Prurigo Nodularis. Participants receive either trial medication or a placebo (something that looks like the trial drug but has no effect on the body), both taken orally. The treatment period will approximately be 13 months including safety follow up.
Currently recruiting

INCB 161734-101

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (NCT06179160)

Currently recruiting

INCMOR 0208-301

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma (INCMOR0208-301) (NCT04680052)

Currently recruiting

INDEPENDENCE

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (The INDEPENDENCE trial) (NCT04717414)

Currently recruiting

INDEX-AF

The role of pharmacological heart failure therapy in LV recovery following INDEX catheter ablation for atrial fibrillation [AF] induced cardiomyopathy - the INDEX-AF Study (ACTRN12625000464460)

A randomised control clinical trial to explore whether patients with AF-induced cardiomyopathy undergoing catheter ablation can avoid anti-heart failure pharmacotherapy. Patients will be randomised to receive anti-heart failure pharmacotherapy (control) versus monitoring without anti-heart failure pharmacotherapy (intervention). The primary outcome will be change in left ventricular ejection fraction from baseline.

Currently recruiting

INFINITE

A Phase III Randomised Crossover Trial to Assess Feasibility of Domiciliary Nasal High Flow for Chronic Breathlessness in People with Interstitial Lung Disease (ACTRN12623000835640p)

Currently recruiting

INFORMED-1

Integrative approaches for Optimizing Recognition, Management and Education of concussion at the community sports level (ACTRN12623000554662)

Currently recruiting

INI-822-001

A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of INI-822 In Healthy Volunteers And Participants With Non-Alcoholic Steatohepatitis [NASH] Or Presumed NASH (NCT05945537)

Currently recruiting

INNOVATE

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons with HIV-1 (NCT07202546)

This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/TAF), to a standard HIV treatment called dolutegravir and lamivudine (DTG/3TC). The purpose of the study is to provide data on the long-term antiviral activity of the VH4524184 and provide information regarding dosing formulation for further evaluations. 

Coming soon

INSIGHT

An International, Phase 3, Randomized, Multicenter, Open label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib (INSIGHT) (NCT05734105)

Currently recruiting

INSPIRE

Invasive assessment of pulmonary microvascular function with novel indices of pulmonary flow reserve and pulmonary microcirculatory resistance. (Trial Not Registered)

Currently recruiting
15 16 17 18 19